Form 8-K - Current report:
SEC Accession No. 0001437749-25-004891
Filing Date
2025-02-24
Accepted
2025-02-24 16:30:30
Documents
17
Period of Report
2025-02-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dmtp20250221_8k.htm   iXBRL 8-K 40435
2 EXHIBIT 10.1 ex_781126.htm EX-10.1 88122
3 EXHIBIT 99.1 ex_781494.htm EX-99.1 10107
8 diamedicalogo.jpg GRAPHIC 6910
  Complete submission text file 0001437749-25-004891.txt   300516

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA dmac-20250220.xsd EX-101.SCH 3409
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dmac-20250220_def.xml EX-101.DEF 11029
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE dmac-20250220_lab.xml EX-101.LAB 14742
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dmac-20250220_pre.xml EX-101.PRE 11134
20 EXTRACTED XBRL INSTANCE DOCUMENT dmtp20250221_8k_htm.xml XML 2731
Mailing Address 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305
Business Address 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305 (763) 496-5454
DiaMedica Therapeutics Inc. (Filer) CIK: 0001401040 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36291 | Film No.: 25657490
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)